LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

Vice president and general manager of UK & Ireland at LEO Pharma, Sarah Kleinpeter, said: “We are pleased that adolescents between 12-17 years of age living with atopic dermatitis will now have ...

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

A recent survey conducted with online opinion panel LEO on behalf of the Regroupement des pharmacies de médicaments de spécialité (RPMSQ) reveals that Quebecers value that they have the ability to ...

The deal replaces a previous, $6 billion agreement that was rejected last July by the Supreme Court because it would have ...

Varadkar has been named as the Hauser Leader of the Harvard Kennedy School Center for Public Leadership for its spring ...

World leaders gather in Poland on Holocaust memorial day, Fed and ECB make rate calls, and the Year of the Snake begins ...

Also in today’s newsletter, a record number of US companies weigh China exit, and Trump calls on Opec to push down global oil prices ...

Long-term treatment with lebrikizumab may be beneficial for patients with atopic dermatitis that were not initially ...